Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Cash & Equivalents: 2009-2025

Historic Cash & Equivalents for UNITED THERAPEUTICS (UTHR) over the last 17 years, with Sep 2025 value amounting to $1.3 billion.

  • UNITED THERAPEUTICS's Cash & Equivalents fell 13.76% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 13.76%. This contributed to the annual value of $1.7 billion for FY2024, which is 40.53% up from last year.
  • UNITED THERAPEUTICS's Cash & Equivalents amounted to $1.3 billion in Q3 2025, which was down 15.88% from $1.6 billion recorded in Q2 2025.
  • UNITED THERAPEUTICS's Cash & Equivalents' 5-year high stood at $1.9 billion during Q1 2025, with a 5-year trough of $795.2 million in Q2 2022.
  • For the 3-year period, UNITED THERAPEUTICS's Cash & Equivalents averaged around $1.4 billion, with its median value being $1.3 billion (2025).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first decreased by 15.60% in 2022, then skyrocketed by 51.81% in 2025.
  • UNITED THERAPEUTICS's Cash & Equivalents (Quarterly) stood at $894.8 million in 2021, then climbed by 7.42% to $961.2 million in 2022, then climbed by 25.65% to $1.2 billion in 2023, then spiked by 40.53% to $1.7 billion in 2024, then dropped by 13.76% to $1.3 billion in 2025.
  • Its Cash & Equivalents was $1.3 billion in Q3 2025, compared to $1.6 billion in Q2 2025 and $1.9 billion in Q1 2025.